Existing users please login

Forgot Password

    Home / Markets / Industries / Health Care

    Monday, November 02, 2009

    Dendreon Files Early for Provenge

    | Respond to Editor | Print

     
    FOXBusiness
       

      Dendreon (DNDN) announced on Monday that its prostate cancer drug Provenge has gone through the Food and Drug Administration application ahead of its 2010 predicted schedule.

      Although Provenge works as a vaccine that stimulates the immune system, it is offered as a treatment for those who have the cancer.

      "With the BLA [Biologics License Application] submission complete, we have taken an important step towards reaching our goal of bringing a new therapy to men with advanced prostate cancer," said Dendreon CEO Mitchell Gold in a company statement.

      The drug is expected to be launched as originally scheduled in 2010 once it gains FDA approval.

      Fox Business Video


      Last 5 Stocks

      • Ticker
      • Company
      • Price
      • Change
       

      Personal Finance - Investing - Financial News - Business News - Stock Market Quotes & News - Small Business

      Advertise with us | Jobs at FOX Business Network | Internships at FBN

      Terms of use. Privacy Statement. For FOXBusiness.com technical issues write to foxbusinessonline@foxbusiness.com; for all other feedback, write to feedback@foxbusiness.com.

      Quotes delayed at least 15 minutes. Market Data provided by Interactive Data (Terms & Conditions). Powered and implemented by Interactive Data Managed Solutions. Company fundamental data provided by Morningstar. Earnings estimates data provided by Zacks. Mutual fund data provided by Lipper. Economic data provided by Econoday. Dow Jones & Company Terms & Conditions.

      This material may not be published, broadcast, rewritten, or redistributed. ©2010 FOX News Network, LLC. All rights reserved.